文献速递肝病

抑制慢加急性肝衰竭患者单核细胞的谷氨酰胺合成酶可恢复其抗菌与炎症能力

Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity.
PubMed 文献 · Gut · 2018-12-22

该研究对慢加急性肝衰竭(ACLF)和失代偿酒精性肝硬化患者的CD14+CD16-单核细胞进行表型与转录组分析,发现ACLF单核细胞呈免疫耐受状态、吞噬与氧化爆发功能受损;用谷氨酰胺合成酶抑制剂进行代谢重编程可部分恢复体外生成及ACLF患者来源单核细胞的吞噬与炎症能力,且谷氨酰胺合成酶/谷氨酰胺酶比值与疾病严重度评分正相关。

要点

  • ACLF患者单核细胞IL-10产生细胞频率升高、HLA-DR表达降低、吞噬与氧化爆发能力受损。
  • ACLF单核细胞转录组上调多种免疫抑制参数,抗菌与抗原提呈机制受损。
  • 谷氨酰胺合成酶抑制剂可部分恢复ACLF患者来源单核细胞的吞噬与炎症能力。

核心结论

  • ACLF中单核细胞呈独特转录谱,极化为免疫耐受状态并伴代谢改变;代谢重编程可部分恢复其功能,为治疗靶向提供新选择。

研究设计与样本

  • 对ACLF和失代偿酒精性肝硬化患者的CD14+CD16-单核细胞进行表型表征后行RNA测序,并建立模拟ACLF患者特征的体外模型研究代谢调节剂对单核细胞功能的影响。

主要发现

  • ACLF患者单核细胞IL-10产生细胞频率升高、HLA-DR表达降低、吞噬与氧化爆发能力受损。
  • ACLF中分离的CD14+CD16-单核细胞转录谱显示多种免疫抑制参数上调、抗菌与抗原提呈机制受损。
  • 失代偿肝硬化患者单核细胞对炎症刺激的应答能力完整。
  • 健康单核细胞在ACLF血浆中培养可模拟患者中观察到的免疫抑制特征,诱导减弱的吞噬应答及与耐受状态相关的代谢程序。
  • 使用谷氨酰胺合成酶药理抑制剂进行代谢重编程可部分恢复体外生成及ACLF患者来源单核细胞的吞噬与炎症能力;ACLF患者来源单核细胞的谷氨酰胺合成酶/谷氨酰胺酶比值与疾病严重度评分正相关。

临床怎么用

  • 作者认为代谢重编程可部分恢复ACLF单核细胞功能,为这些患者的治疗靶向开辟新选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Acute-on-chronic liver failure (ACLF) is associated with dysfunctional circulating monocytes whereby patients become highly susceptible to bacterial infections. Here, we identify the pathways underlying monocyte dysfunction in ACLF and we investigate whether metabolic rewiring reinstates their phagocytic and inflammatory capacity. DESIGN: Following phenotypic characterisation, we performed RNA sequencing on CD14+CD16- monocytes from patients with ACLF and decompensated alcoholic cirrhosis. Additionally, an in vitro model mimicking ACLF patient-derived features was implemented to investigate the efficacy of metabolic regulators on monocyte function. RESULTS: Monocytes from patients with ACLF featured elevated frequencies of interleukin (IL)-10-producing cells, reduced human leucocyte antigen DR isotype (HLA-DR) expression and impaired phagocytic and oxidative burst capacity. Transcriptional profiling of isolated CD14+CD16- monocytes in ACLF revealed upregulation of an array of immunosuppressive parameters and compromised antibacterial and antigen presentation machinery. In contrast, monocytes in decompensated cirrhosis showed intact capacity to respond to inflammatory triggers. Culturing healthy monocytes in ACLF plasma mimicked the immunosuppressive characteristics observed in patients, inducing a blunted phagocytic response and metabolic program associated with a tolerant state. Metabolic rewiring of the cells using a pharmacological inhibitor of glutamine synthetase, partially restored the phagocytic and inflammatory capacity of in vitro generated- as well as ACLF patient-derived monocytes. Highlighting its biological relevance, the glutamine synthetase/glutaminase ratio of ACLF patient-derived monocytes positively correlated with disease severity scores. CONCLUSION: In ACLF, monocytes feature a distinct transcriptional profile, polarised towards an immunotolerant state and altered metabolism. We demonstrated that metabolic rewiring of ACLF monocytes partially revives their function, opening up new options for therapeutic targeting in these patients.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Korf H, du Plessis J, van Pelt J, et al. Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity. Gut. 2018. PMID: 30580251. doi:10.1136/gutjnl-2018-316888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。